Ucb SA
DUS:UNC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
U
|
Ucb SA
DUS:UNC
|
BE |
|
US Nuclear Corp
OTC:UCLE
|
US |
|
Idorsia Ltd
SIX:IDIA
|
CH |
|
B
|
Battalion Oil Corp
F:RAQB
|
US |
|
K
|
K&O Energy Group Inc
TSE:1663
|
JP |
|
Wijaya Karya (Persero) Tbk PT
F:5AA
|
ID |
|
Intouch Insight Ltd
XTSX:INX
|
CA |
|
Odfjell SE
F:O7F
|
NO |
|
Bally's Corp
F:358
|
US |
|
B
|
Boryszew SA
XMUN:BOW
|
PL |
Intrinsic Value
Is UNC undervalued or overvalued?
See the intrinsic value estimate for 
Ucb SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
UNC looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with UNC’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Ucb Does
UCB SA is a Belgian biopharmaceutical company that develops and sells prescription medicines for people with serious immune and nervous system diseases. Its main products are treatments for conditions such as epilepsy, Parkinson’s-related movement problems, and immune-mediated disorders like psoriasis, arthritis, and other autoimmune diseases. The company spends heavily on research and clinical testing because its business depends on discovering, proving, and getting approval for new medicines.
- Headquarters
- Belgium BE
- Employees
- 9 765
- IPO date
- Jan 2, 1987
Earnings Waterfall
Ucb SA
The intrinsic value for Ucb SA (UNC) under the Base Case is hidden EUR.
Compared with the current market price of 201.8 EUR, the stock appears hidden.